Celularity Enters Strategic Collaboration Agreement with Clinical Stage Cell Therapy Company

Core Insights - Celularity Inc. has entered into a Master Services Collaboration Agreement with BlueSphere Bio, Inc. to manufacture certain cell therapy products, showcasing its advanced cGMP manufacturing capabilities [1][2] - The collaboration will focus on producing BlueSphere's novel T cell receptor (TCR) therapies, including a product for treating Acute Myelogenous Leukemia (AML) [2][3] - Celularity aims to leverage its manufacturing infrastructure to attract clients and generate revenue, while BlueSphere emphasizes the importance of reliable manufacturing for its clinical programs [3][5] Company Overview - Celularity Inc. specializes in regenerative and cellular medicine, developing placental-derived cell therapies and biomaterial products [4] - The company utilizes postpartum placenta to create therapeutic solutions addressing unmet global healthcare needs [4] BlueSphere Bio Overview - BlueSphere Bio is focused on drug development, particularly in AML, with its lead product BSB-1001 targeting specific antigens in high-risk patients [5][6] - The company is advancing its clinical programs, including TCX-101 and TCX-102, with plans to dose its first patient in 1H2025 [5][6]